Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.American biotech firm Abmaxis is to collaborate with the Swedish firm BioArctic Neuroscience in the pursuit of a therapeutic human monoclonal antibody for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
Using its antibody technology, Abmaxis will further optimize and humanize antibodies developed by BioArctic.
Under the terms of the agreement, BioArctic will pay Abmaxis an upfront technology license fee. Abmaxis is also entitled to receive future milestone payments and royalties on product sales.
BioArctic’s new antibody treatment strategy is based on discoveries made by Professor Lars Lannfelt and his research team at Uppsala University. He discovered the Arctic mutation in familial Alzheimer’s disease and identified a toxic component considered to cause the disease. BioArctic has developed murine monoclonal antibodies targeting this component.
“We consider the BioArctic target to be a unique discovery that could lead to the development of a new type of immunotherapy for Alzheimer’s disease,” stated Dr Peter Luo, chief technology officer of Abmaxis. “We are confident of our ability to successfully develop and optimize the drug candidate.”